Treatment

Trimodulin (human IgM clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.
For: Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)
Belgium · Austria · Slovakia